Ludwig Enterprises, Inc.

What they do

Ludwig Enterprises is developing mRNA-based screening tests for inflammation-related chronic diseases, including cancer. Its first product candidate, the Revealia Breast test, uses a non-invasive cheek swab to collect mRNA samples. The company plans to offer home collection kits directly to patients and enable CLIA-certified laboratories to provide the test as a Laboratory Developed Test (LDT).

Revenue drivers

• Revealia Breast test — Planned product candidate for breast cancer screening, trial-launch anticipated in Q2 2026; no revenue generated yet.
• B2B2C home collection kits — Intended to sell directly to patients and through partnerships with CLIA-certified laboratories; not yet commercialized.
• mRNA biomarker technology — Platform integrates mRNA inflammatory biomarkers and machine-learning algorithms; potential applications beyond breast cancer, but no current revenue.

Recent performance

For the three months ended March 31, 2026, the company reported net income of $218,847 (unaudited), but net cash used in operating activities of $152,659. At March 31, 2026, it had a working capital deficit of $5,037,861, an accumulated deficit of $9,276,952, and stockholders' deficit of $4,028,695. Annual net income has been negative for 2022-2025, with 2025 net loss of $2.2 million. Cash and equivalents were $18,323 as of March 31, 2026.

Strategy

Management's stated strategy is to commercialize the Revealia Breast test through a B2B2C model, offering home collection kits supported by genetic counselors and partnering with CLIA-certified laboratories. The company plans to rely on its two patent families covering mRNA-based diagnostics in multiple jurisdictions. It intends to seek funding for clinical validation studies, laboratory infrastructure, and distribution capabilities. Recent corporate actions include a proposed reverse stock split and name change to Revealia Diagnostics, Inc.

Risks

• No revenue and limited cash — The company has no commercial products, minimal revenue, and only $18,323 in cash, raising substantial doubt about its ability to continue operations.
• Dependence on external funding — Commercialization plans are explicitly dependent on securing funding for clinical validation, infrastructure, and distribution, which may not be available.
• Early-stage product development — The Revealia Breast test is not yet launched and may fail to obtain regulatory approval or market acceptance.
• Significant accumulated deficit — Accumulated deficit of $9.3 million and stockholders' deficit of $4.0 million could impair ability to raise capital and sustain operations.

Outlook

Management anticipates trial-launching the Revealia Breast test in the second quarter of 2026. They expect continued losses over the next twelve months and believe it is likely they will sustain losses. The company's ability to execute its plan is contingent on raising additional capital, which is uncertain.